Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Archives of Virology
Published in: Archives of Virology 5/2008

01-05-2008 | Rapid Communication

Search for cellular partners of human papillomavirus type 16 E2 protein

Authors: Agnieszka K. Olejnik-Schmidt, Marcin T. Schmidt, Witold Kędzia, Anna Goździcka-Józefiak

Published in: Archives of Virology | Issue 5/2008

Login to get access

Abstract

Human papillomaviruses (HPVs) are small, double-stranded DNA viruses that infect cutaneous and mucosal epithelia. Type 16 (HPV16) displays tropism to genital epithelia, giving rise to genital warts and cervical intraepithelial neoplasia (CIN), which is a precursor lesion to invasive carcinoma of the cervix. The great majority of human cervical cancers contain integrated HPV DNA where the E2 gene is usually disrupted, suggesting that the loss of the E2 protein is an important step in HPV-induced carcinogenesis. The HPV16 E2 protein is a regulatory protein that seems to be essential for creating favourable conditions for establishment of infection and proper completion of the viral life cycle. Recently, diverse activities of the E2 proteins have been described, but the molecular basis of these processes has not beenfully elucidated. Using a yeast two-hybrid system, we have identified epithelial cellular proteins that bind to the E2 protein of HPV16.
Literature
1.
Asumalahti K, Laitinen T, Itkonen-Vatjus R, Lokki ML, Suomela S, Snellman E, Saarialho-Kere U, Kere J (2000) A candidate gene for psoriasis near HLA-C, HCR (Pg8), is highly polymorphic with a disease-associated susceptibility allele. Hum Mol Genet 9:1533–1542PubMedCrossRef
2.
Asumalahti K, Veal C, Laitinen T, Suomela S, Allen M, Elomaa O, Moser M, de Cid R, Ripatti S, Vorechovsky I, Marcusson JA, Nakagawa H, Lazaro C, Estivill X, Capon F, Novelli G, Saarialho-Kere U, Barker J, Trembath R, Kere J (2002) Coding haplotype analysis supports HCR as the putative susceptibility gene for psoriasis at the MHC PSORS1 locus. Hum Mol Genet 11:589–597PubMedCrossRef
3.
Ballabeni A, Melixetian M, Zamponi R, Masiero L, Marinoni F, Helin K (2004) Human geminin promotes pre-RC formation and DNA replication by stabilizing CDT1 in mitosis. EMBO J 23:3122–3132PubMedCrossRef
4.
Bastien N, McBride AA (2000) Interaction of the papillomavirus E2 protein with mitotic chromosomes. Virology 270:124–134PubMedCrossRef
5.
Benson JD, Lawande R, Howley PM (1997) Conserved interaction of the papillomavirus E2 transcriptional activator proteins with human and yeast TFIIB proteins. J Virol 71:8041–8047PubMed
6.
Boner W, Morgan IM (2002) Novel cellular interacting partners of the human papillomavirus 16 transcription/replication factor E2. Virus Res 90:113–118PubMedCrossRef
7.
Boner W, Taylor ER, Tsirimonaki E, Yamane K, Campo MS, Morgan IM (2002) A functional interaction between the human papillomavirus 16 transcription/replication factor E2 and the DNA damage response protein TopBP1. J Biol Chem 277:22297–22303PubMedCrossRef
8.
Bouvard V, Storey A, Pim D, Banks L (1994) Characterization of the human papillomavirus E2 protein: evidence of trans-activation and trans-repression in cervical keratinocytes. EMBO J 13:5451–5459PubMed
9.
Breiding DE, Sverdrup F, Grossel MJ, Moscufo N, Boonchai W, Androphy EJ (1997) Functional interaction of a novel cellular protein with the papillomavirus E2 transactivation domain. Mol Cell Biol 17:7208–7219PubMed
10.
Carim-Todd L, Sumoy L, Andreu N, Estivill X, Escarceller M (2001) Identification and characterization of BTBD1, a novel BTB domain containing gene on human chromosome 15q24. Gene 262:275–281PubMedCrossRef
11.
Cheng LE, Chan FK, Cado D, Winoto A (1997) Functional redundancy of the Nur77 and Nor-1 orphan steroid receptors in T-cell apoptosis. EMBO J 16:1865–1875PubMedCrossRef
12.
Collins T, Stone JR, Williams AJ (2001) All in the family: the BTB/POZ, KRAB, and SCAN domains. Mol Cell Biol 21:3609–3615PubMedCrossRef
13.
Cripe TP, Haugen TH, Turk JP, Tabatabai F, Schmid PG, Durst M, Gissmann L, Roman A, Turek LP (1987) Transcriptional regulation of the human papillomavirus-16 E6-E7 promoter by a keratinocyte-dependent enhancer, and by viral E2 trans- activator and repressor gene products: implications for cervical carcinogenesis. EMBO J 6:3745–3753PubMed
14.
Defrancesco L, Wilkinson D (1999) The two body problem. Scientist 13:21–23
15.
Demeret C, Yaniv M, Thierry F (1994) The E2 transcriptional repressor can compensate for Sp1 activation of the human papillomavirus type 18 early promoter. J Virol 68:7075–7082PubMed
16.
Demeret C, Garcia-Carranca A, Thierry F (2003) Transcription-independent triggering of the extrinsic pathway of apoptosis by human papillomavirus 18 E2 protein. Oncogene 22:168–175PubMedCrossRef
17.
Desaintes C, Demeret C, Goyat S, Yaniv M, Thierry F (1997) Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. EMBO J 16:504–514PubMedCrossRef
18.
Desaintes C, Goyat S, Garbay S, Yaniv M, Thierry F (1999) Papillomavirus E2 induces p53-independent apoptosis in HeLa cells. Oncogene 18:4538–4545PubMedCrossRef
19.
Dey A, Ellenberg J, Farina A, Coleman AE, Maruyama T, Sciortino S, Lippincott-Schwartz J, Ozato K (2000) A bromodomain protein, MCAP, associates with mitotic chromosomes and affects G2-to-M transition. Mol Cell Biol 20:6537–6549PubMedCrossRef
20.
Dowhanick JJ, McBride AA, Howley PM (1995) Suppression of cellular proliferation by the papillomavirus E2 protein. J Virol 69:7791–7799PubMed
21.
Dunphy EL, Johnson T, Auerbach SS, Wang EH (2000) Requirement for TAF(II)250 acetyltransferase activity in cell cycle progression. Mol Cell Biol 20:1134–1139PubMedCrossRef
22.
Fleckenstein DS, Dirks WG, Drexler HG, Quentmeier H (2003) Tumor necrosis factor receptor-associated factor (TRAF) 4 is a new binding partner for the p70S6 serine/threonine kinase. Leuk Res 27:687–694PubMedCrossRef
23.
Fujii T, Brandsma JL, Peng X, Srimatkandada S, Li L, Canaan A, Deisseroth AB (2001) High and low levels of cottontail rabbit papillomavirus E2 protein generate opposite effects on gene expression. J Biol Chem 276:867–874PubMedCrossRef
24.
Fournier N, Raj K, Saudan P, Utzig S, Sahli R, Simanis V, Beard P (1999) Expression of human papillomavirus 16 E2 protein in Schizosaccharomyces pombe delays the initiation of mitosis. Oncogene 18:4015–4021PubMedCrossRef
25.
Futcher AB, Cox BS (1984) Copy number and the stability of 2-micron circle-based artificial plasmids of Saccharomyces cerevisiae. J Bacteriol 57:283–290
26.
Gandhi TK, Zhong J, Mathivanan S, Karthick L, Chandrika KN, Mohan SS, Sharma S, Pinkert S, Nagaraju S, Periaswamy B, Mishra G, Nandakumar K, Shen B, Deshpande N, Nayak R, Sarker M, Boeke JD, Parmigiani G, Schultz J, Bader JS, Pandey A (2006) Analysis of the human protein interactome and comparison with yeast, worm and fly interaction datasets. Nat Genet 38:285–293PubMedCrossRef
27.
Garcia JA, Ou SH, Wu F, Lusis AJ, Sparkes RS, Gaynor RB (1992) Cloning and chromosomal mapping of a human immunodeficiency virus 1 “TATA” element modulatory factor. Proc Natl Acad Sci USA 89:9372–9376PubMedCrossRef
28.
Giri I, Yaniv M (1988) Structural and mutational analysis of E2 trans-activating proteins of papillomaviruses reveals three distinct functional domains. EMBO J 7:2823–2829PubMed
29.
Gish W, States DJ (1993) Identification of protein coding regions by database similarity search. Nat Genet 3:266–272PubMedCrossRef
30.
Goodwin EC, Naeger LK, Breiding DE, Androphy EJ, DiMaio D (1998) Transactivation-competent bovine papillomavirus E2 protein is specifically required for efficient repression of human papillomavirus oncogene expression and for acute growth inhibition of cervical carcinoma cell lines. J Virol 72:3925–3934PubMed
32.
Ham J, Steger G, Yaniv M (1994) Cooperativity in vivo between the E2 transactivator and the TATA box binding protein depends on core promoter structure. EMBO J 13:147–157PubMed
32.
Ham J, Dostatni N, Gauthier JM, Yaniv M (1991) The papillomavirus E2 protein: a factor with many talents. Trends Biochem Sci 16:440–444PubMedCrossRef
33.
Howley PM (1996) Papillomavirinae the viruses and their replication. In: Fields BN, Knipe DM, Howley PM (eds) Virology, 2nd edn. Lippincott-Raven Publishers, Philadelphia, pp 2045–2076
34.
Hwang ES, Riese DJ, Settleman J, Nilson LA, Honig J, Flynn S, DiMaio D (1993) Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine papillomavirus regulatory gene. J Virol 67:3720–3729PubMed
35.
Hwang ES, Naeger LK, DiMaio D (1996) Activation of the endogenous p53 growth inhibitory pathway in HeLa cervical carcinoma cells by expression of the bovine papillomavirus E2 gene. Oncogene 12:795–803PubMed
36.
Klucevsek K, Wertz M, Lucchi J, Leszczynski A, Moroianu J (2007) Characterization of the nuclear localization signal of high risk HPV16 E2 protein. Virology 360:191–198PubMedCrossRef
37.
Kovelman R, Bilter GK, Glezer E, Tsou AY, Barbosa MS (1996) Enhanced transcriptional activation by E2 proteins from the oncogenic human papillomaviruses. J Virol 70:7549–7560PubMed
38.
Lambert PF, Dostatni N, McBride AA, Yaniv M, Howley PM, Arcangioli B (1989) Functional analysis of the papilloma virus E2 trans-activator in Saccharomyces cerevisiae. Genes Dev 3:38–48PubMedCrossRef
39.
Lee D, Lee B, Kim J, Kim DW, Choe J (2000) cAMP response element-binding protein-binding protein binds to human papillomavirus E2 protein and activates E2-dependent transcription. J Biol Chem 275:7045–7051PubMedCrossRef
40.
Lee KY, Broker TR, Chow LT (1998) Transcription factor YY1 represses cell-free replication from human papillomavirus origins. J Virol 72:4911–4917PubMed
41.
Lee JM, Lee K, Weidner M, Osborne BA, Hayward SD (2002) Epstein-Barr virus EBNA2 blocks Nur77-mediated apoptosis. Proc Natl Acad Sci USA 99:11878–11883PubMedCrossRef
42.
Lehman CW, King DS, Botchan MR (1997) A papillomavirus E2 phosphorylation mutant exhibits normal transient replication and transcription but is defective in transformation and plasmid retention. J Virol 71:3652–3665PubMed
43.
Li H, Kolluri SK, Gu J, Dawson MI, Cao X, Hobbs PD, Lin B, Chen G, Lu J, Lin F, Xie Z, Fontana JA, Reed JC, Zhang X (2000) Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science 289:1159–1164PubMedCrossRef
44.
Lopez R, Garrido E, Vazquez G, Pina P, Perez C, Alvarado I, Salcedo M (2006) A subgroup of HOX Abd-B gene is differentially expressed in cervical cancer. Int J Gynecol Cancer 16:1289–1296PubMedCrossRef
45.
Lu JZ, Sun YN, Rose RC, Bonnez W, McCance DJ (1993) Two E2 binding sites (E2BS) alone or one E2BS plus an A/T-rich region are minimal requirements for the replication of the human papillomavirus type 11 origin. J Virol 67:7131–7139PubMed
46.
Maruyama T, Farina A, Dey A, Cheong J, Bermudez VP, Tamura T, Sciortino S, Shuman J, Hurwitz J, Ozato K (2002) A Mammalian bromodomain protein, brd4, interacts with replication factor C and inhibits progression to S phase. Mol Cell Biol 22:6509–6520PubMedCrossRef
47.
Massimi P, Pim D, Bertoli C, Bouvard V, Banks L (1999) Interaction between the HPV-16 E2 transcriptional activator and p53. Oncogene 18:7748–7754PubMedCrossRef
48.
McPhillips MG, Oliveira JG, Spindler JE, Mitra R, McBride AA (2006) Brd4 is required for e2-mediated transcriptional activation but not genome partitioning of all papillomaviruses. J Virol 80:9530–9543PubMedCrossRef
49.
Montanari M, Boninsegn A, Faraglia B, Coco C, Giordano A, Cittadini A, Sgambato A (2005) Increased expression of geminin stimulates the growth of mammary epithelial cells and is a frequent event in human tumors. J Cell Physiol 202:215–222PubMedCrossRef
50.
Morrissey LC, Barsoum J, Androphy EJ (1989) Trans activation by the bovine papillomavirus E2 protein in Saccharomyces cerevisiae. J Virol 63:4422–4425PubMed
51.
O’Brien T, Tjian R (1998) Functional analysis of the human TAFII250 N-terminal kinase domain. Mol Cell 1:905–911PubMedCrossRef
52.
Okabe T, Takayanagi R, Adachi M, Imasaki K, Nawata H (1998) Nur77, a member of the steroid receptor superfamily, antagonizes negative feedback of ACTH synthesis and secretion by glucocorticoid in pituitary corticotrope cells. J Endocrinol 156:169–175PubMedCrossRef
53.
Olejnik-Schmidt AK, Schmidt MT, Gozdzicka-Jozefiak A (2006) Orphan nuclear hormone receptor NR4A1 interacts with HPV16 E2 regulatory protein. Cell Mol Biol Lett 11:102–108PubMedCrossRef
54.
Pham AD, Sauer F (2000) Ubiquitin-activating/conjugating activity of TAFII250, a mediator of activation of gene expression in Drosophila. Science 289:2357–2360PubMedCrossRef
55.
Rank NM, Lambert PF (1995) Bovine papillomavirus type 1 E2 transcriptional regulators directly bind two cellular transcription factors, TFIID and TFIIB. J Virol 69:6323–6334PubMed
56.
Remm M, Brain R, Jenkins JR (1992) The E2 binding sites determine the efficiency of replication for the origin of human papillomavirus type 18. Nucleic Acids Res 20:6015–6021PubMedCrossRef
57.
Romanczuk H, Thierry F, Howley PM (1990) Mutational analysis of cis elements involved in E2 modulation of human papillomavirus type 16 P97 and type 18 P105 promoters. J Virol 64:2849–2859PubMed
58.
Sakai H, Yasugi T, Benson JD, Dowhanick JJ, Howley PM (1996) Targeted mutagenesis of the human papillomavirus type 16 E2 transactivation domain reveals separable transcriptional activation and DNA replication functions. J Virol 70:1602–1611PubMed
59.
Sax JK, El-Deiry WS (2003) Identification and characterization of the cytoplasmic protein TRAF4 as a p53-regulated proapoptotic gene. J Biol Chem 278:36435–36444PubMedCrossRef
60.
Schweiger MR, You J, Howley PM (2006) Bromodomain protein 4 mediates the papillomavirus E2 transcriptional activation function. J Virol 80:4276–4285PubMedCrossRef
61.
Sedman J, Stenlund A (1995) Co-operative interaction between the initiator E1 and the transcriptional activator E2 is required for replicator specific DNA replication of bovine papillomavirus in vivo and in vitro. EMBO J 14:6218–6228PubMed
62.
Sedman J, Stenlund A (1996) The initiator protein E1 binds to the bovine papillomavirus origin of replication as a trimeric ring-like structure. EMBO J 15:5085–5092PubMed
63.
Sedman T, Sedman J, Stenlund A (1997) Binding of the E1 and E2 proteins to the origin of replication of bovine papillomavirus. J Virol 71:2887–2896PubMed
64.
Skiadopoulos MH, McBride AA (1998) Bovine papillomavirus type 1 genomes and the E2 transactivator protein are closely associated with mitotic chromatin. J Virol 72:2079–2088PubMed
65.
Steger G, Corbach S (1997) Dose-dependent regulation of the early promoter of human papillomavirus type 18 by the viral E2 protein. J Virol 71:50–58PubMed
66.
Steger G, Ham J, Lefebvre O, Yaniv M (1995) The bovine papillomavirus 1 E2 protein contains two activation domains: one that interacts with TBP and another that functions after TBP binding. EMBO J 14:329–340PubMed
67.
Steger G, Schnabel C, Schmidt HM (2002) The hinge region of the human papillomavirus type 8 E2 protein activates the human p21(WAF1/CIP1) promoter via interaction with Sp1. J Gen Virol 83:503–510PubMed
68.
Strasswimmer J, Lorson CL, Breiding DE, Chen JJ, Le T, Burghes AH, Androphy EJ, (1999) Identification of survival motor neuron as a transcriptional activator- binding protein. Hum Mol Genet 8:1219–1226PubMedCrossRef
69.
Tan SH, Gloss B, Bernard HU (1992) During negative regulation of the human papillomavirus-16 E6 promoter, the viral E2 protein can displace Sp1 from a proximal promoter element. Nucleic Acids Res 20:251–256PubMedCrossRef
70.
Tan SH, Leong LE, Walker PA, Bernard HU (1994) The human papillomavirus type 16 E2 transcription factor binds with low cooperativity to two flanking sites and represses the E6 promoter through displacement of Sp1 and TFIID. J Virol 68:6411–6420PubMed
71.
Tanackovic G, Kramer A (2005) Human splicing factor SF3a, but not SF1, is essential for pre-mRNA splicing in vivo. Mol Biol Cell 16:1366–1377PubMedCrossRef
72.
Utley RT, K Ikeda, Grant PA, Cote J, Steger DJ, Eberharter A, John S, Workman JL (1998) Transcriptional activators direct histone acetyltransferase complexes to nucleosomes. Nature 394:498–502PubMedCrossRef
73.
Voitenleitner C, Botchan M (2002) E1 protein of bovine papillomavirus type 1 interferes with E2 protein- mediated tethering of the viral DNA to mitotic chromosomes. J Virol 76:3440–3451PubMedCrossRef
74.
Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3:430–440PubMedCrossRef
75.
Wassarman DA, Sauer F (2001) TAF(II)250: a transcription toolbox. J Cell Sci 114:2895–2902PubMed
76.
Webster K, Parish J, Pandya M, Stern PL, Clarke AR, Gaston K (2000) The human papillomavirus (HPV) 16 E2 protein induces apoptosis in the absence of other HPV proteins and via a p53-dependent pathway. J Biol Chem 275:87–94PubMedCrossRef
77.
Wu SY, Lee AY, Hou SY, Kemper JK, Erdjument-Bromage H, Tempst P, Chiang CM (2006) Brd4 links chromatin targeting to HPV transcriptional silencing. Genes Dev 20:2383–2396PubMedCrossRef
78.
Xu L, Yang L, Hashimoto K, Anderson M, Kohlhagen G, Pommier Y, D’Arpa P (2002) Characterization of BTBD1 and BTBD2, two similar BTB-domain-containing Kelch-like proteins that interact with Topoisomerase I. BMC Genomics 3:1PubMedCrossRef
79.
Xu YC, Wu RF, Gu Y, Yang YS, Yang MC, Nwariaku FE, Terada LS (2002) Involvement of TRAF4 in oxidative activation of c-Jun N-terminal kinase. J Biol Chem 277:28051–28057PubMedCrossRef
80.
Yao JM, Breiding DE, Androphy EJ (1998) Functional interaction of the bovine papillomavirus E2 transactivation domain with TFIIB. J Virol 72:1013–1019PubMed
81.
You J, Croyle JL, Nishimura A, Ozato K, Howley PM (2004) Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. Cell 117:349–360PubMedCrossRef
82.
Zhang D, Paley AJ, Childs G (1998) The transcriptional repressor ZFM1 interacts with and modulates the ability of EWS to activate transcription. J Biol Chem 273:18086–18091PubMedCrossRef
Metadata
Title
Search for cellular partners of human papillomavirus type 16 E2 protein
Authors
Agnieszka K. Olejnik-Schmidt
Marcin T. Schmidt
Witold Kędzia
Anna Goździcka-Józefiak
Publication date
01-05-2008
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 5/2008
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-008-0061-6

Other articles of this Issue 5/2008

Archives of Virology 5/2008 Go to the issue

Original Article

Yams (Dioscorea spp.) from the South Pacific Islands contain many novel badnaviruses: implications for international movement of yam germplasm

Brief Report

Identification of a new Apscaviroid from Japanese persimmon

Original Article

Genetic variability of genome segments 3 and 9 of Fiji disease virus field isolates

Brief Report

Effects of oseltamivir phosphate (Tamiflu®) in human sera on results of microneutralization and hemagglutinin-inhibition tests for H5N2 avian influenza virus

Original Article

Rabbit hemorrhagic disease virus poly(A) tail is not essential for the infectivity of the virus and can be restored in vivo

Original Article

Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits